March 2025
deepLive™ receives FDA 510(k) clearance from the Food & Drug Administration (FDA)
Read More
See beyond appearances
1 in 3 cancers is a skin cancer
Skin cancer is the most commonly occurring cancer in humans, with an incidence that has steadily increased worldwide. The prognosis of advanced melanoma is poor, and carcinomas are associated with high morbidity.
60% biopsies result in benign diagnoses
Although dermoscopy is a useful tool for clinical examination, the sensitivity of dermoscopic monitoring is limited by melanomas that may arise in normal skin or in clinically benign nevi that were not initially photographed (link).
20% skin cancers missed at early stage
Dermoscopy improves the diagnostic accuracy for melanoma but only for experienced examiners. Dermoscopy by untrained or less experienced examiners is no better than clinical inspection without dermoscopy (link).
Discover deepLive™
Damae Medical develops deepLive™ medical device, the new best-in-class imaging system pairing penetration and cellular resolution in 3D. deepLive™ is adapted to the imaging of multiple skin conditions, promoting efficient, reassuring and non-invasive patient management.
Based on LC-OCT™ innovative technology
deepLive™ integrates LC-OCT (Line-field Confocal Optical Coherence Tomography) technology which provides a unique 3D imaging modality, allowing the user to switch from a histology-like vertical mode to a confocal-like horizontal mode,
and to record a 3D stack of tissue volumes in situ.
Navigations in LC-OCT™ 3D stacks
LC-OCT™ imaging of the back of a hand
.png)
LC-OCT™ imaging of a fingerprint
User Testimonial
Prof. Mariano Suppa from the Dermatology Department of the Erasme Hospital, ULB Brussels, shares his experience with deepLive™.
LIST OF PUBLICATIONS
Access to the library on Zotero.org
Quantitative skin analyses
adapted to your studies
-
Skin Surface 3D segmentation
-
Dermo-Epidermal Junction 3D segmentation
-
Keratinocytes distribution
-
Keratinocytes density with depth
-
Collagen fibers segmentation
Our company
2014
Company established by Anaïs BARUT (CEO), David SIRET (CTO), Arnaud DUBOIS (CSO) who filed the patent protecting LC-OCT's technology
2015
Validation of the potential of LC-OCT 2D imaging for the 2 main types of skin cancer: carcinoma and melanoma
2016
First clinical demonstrator installed at the Saint-Etienne University Hospital
2017
Closing of a €2 million investment round with Kurma Partners, Idinvest Partners, News Invest, Paris-Saclay Seed Fund co-managed by Partech Ventures, and private investors
2018
First scientific publication: A. Dubois and al., “LC-OCT for high-resolution noninvasive imaging of skin tumors”, JBO 23, 106007
2019
Miniaturized LC-OCT 3D in a handheld probe
Manufacturing of 10 LC-OCT 3D devices
Launch of clinical validation of LC-OCT 3D
2020
Integration of the live dermoscopic camera inside the LC-OCT 3D handheld probe
2021
Implementation of a scalable production strategy with industrial partners
2022
Damae Medical raises €5M in Series A Financing
2023
deepLive™ receives CE Mark Class IIA under EU MDR 2017/745
2024
deepLive™ installations in over 10 countries in Europe, Japan, Australia and the United States
Publication of the 170th scientific paper on
LC-OCT and its applications
Prof. Arnaud Dubois presents LC-OCT technology
3 key numbers in the development of Damae Medical
Contact us
Damae Medical
14 rue Sthrau
75013 Paris
France
If you are looking for a position or an internship, send your CV on this page:
www.damae-medical.nous-recrutons.fr
We will get back to you as soon as possible!